Pulmonx Corporation — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; the supplied text does not provide a clear standalone fourth-quarter financial breakdown.
Business context
Pulmonx is a commercial-stage medical technology company focused on minimally invasive treatment of severe emphysema. Its solution combines the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform. The Zephyr Valve is the company’s primary revenue driver; StratX supports patient selection but does not independently generate revenue. The company reports sales in more than 25 countries and more than 25,000 patients treated with over 100,000 valves.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $68.7 million | $53.7 million |
| Gross profit / gross margin | $50.8 million / 73.9% | $39.9 million / 74.3% |
| Operating expenses | $112.7 million | $98.5 million |
| Loss from operations | $61.9 million | $58.6 million |
| Net loss | $60.8 million | $58.9 million |
| Net loss per share, basic and diluted | $1.60 | $1.59 |
| Cash used in operating activities | $37.6 million | $45.1 million |
Revenue increased 28.0%, reflecting higher Zephyr procedure volumes. U.S. revenue was $45.9 million, up from $32.5 million; international revenue was $22.8 million, up from $21.2 million. Gross margin declined 0.4 percentage points as cost of goods sold grew faster than revenue. R&D expense rose 17.4% to $18.1 million and selling, general and administrative expense rose 13.8% to $94.6 million, principally reflecting personnel-related costs, including stock-based compensation.
At year-end, cash, cash equivalents and marketable securities totaled $131.5 million, down from $147.1 million in 2022. Cash and cash equivalents were $83.5 million; marketable securities were $47.9 million. The company reported $37.2 million of debt, net of debt discounts and issuance costs, and $45.7 million of scheduled future debt and interest payments. The CIBC loan has a stated maturity of October 2027, a floating rate, and an effective annual interest rate of 10.1% at year-end. Pulmonx reported compliance with its loan covenants.
Total assets were $177.8 million, total liabilities $59.5 million and stockholders’ equity $118.3 million. Accumulated deficit was $411.2 million. Inventory totaled $19.3 million, including $2.6 million classified as long-term inventory.
Material changes, outlook and risks
- Operating cash use improved by $7.5 million year over year, while net loss increased by $1.9 million. Financing cash flow included a $20.0 million CIBC borrowing in February 2023.
- Management expects continued net losses for the next several years and continued investment in sales, marketing, R&D and clinical programs. It believes available cash, cash equivalents and marketable securities will fund planned operations for at least 12 months from issuance of the financial statements. The filing provides no specific revenue or earnings guidance.
- Management may require additional capital; future equity or debt financing may be unavailable or may dilute stockholders or impose restrictive terms. The company’s cash-runway estimate depends on assumptions that may prove incorrect.
- In December 2022, the company received a Department of Justice civil investigative demand concerning an investigation under the Anti-Kickback Statute and False Claims Act into certain healthcare-provider, medical-practice and hospital relationships. Pulmonx is cooperating but cannot estimate the outcome or reasonably possible loss; the matter could materially affect results, financial condition or the business.
- Key operating risks include dependence on the Zephyr Valve and severe-emphysema indication, adoption and reimbursement uncertainty, competition, single-source suppliers and concentrated manufacturing, and regulatory requirements. Medicare has no national or local coverage determination for endobronchial valves; coverage is generally assessed case by case.
- Zephyr treatment carries serious risks, particularly pneumothorax. Pneumothoraces occurred in 18%–34% of treated patients in clinical trials; the filing also reports four treatment-period deaths in the LIBERATE trial’s valve group. The company notes that longer-term safety and effectiveness evidence remains in follow-up, including ongoing data analysis for the LIBERATE extension study.
- The auditor issued an unqualified opinion on the financial statements. Inventory classification was identified as a critical audit matter because it depends on management’s forecast of future product demand. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2023.
Important facts for investors to verify
- Developments and any potential financial or operational consequences of the DOJ investigation.
- Actual cash burn, liquidity runway and compliance with CIBC minimum-cash and revenue covenants as sales and spending evolve.
- Growth in procedure volumes, U.S. adoption and international sales, alongside changes in gross margin and operating expenses.
- Coverage and reimbursement decisions, prior-authorization outcomes and any changes to Medicare or commercial-payor policies.
- Inventory demand assumptions, long-term inventory utilization and any future write-downs.
- Updated clinical evidence, including LIBERATE extension results, and progress, timing and funding needs for AeriSeal and other development programs.